SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
VentiRx Pharmaceuticals, Inc.' Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology